Telehealth GLP-1 prescriptions
A GLP-1 weight-loss program that bundles the medication with glycine, B12 and B6 and a weekly body scan. It is a separate company from Hume Health, which we review on its own page.
We may earn a commission if you buy through the links to HumeCare+ on this page, at no extra cost to you. That does not change how we grade or rank it, and HumeCare+ did not write or approve this review.
quality claims we could confirm ourselves, rather than repeat from the vendor's marketing.
A personalized GLP-1 protocol with supporting nutrients, prescribed after an online assessment.
Everything here is a prescription service that starts with a licensed clinician's review of your own health information. Compounded medications are made by a pharmacy against a prescription and are not FDA-approved or reviewed by the FDA for safety, effectiveness or quality. This entry describes what the brand offers and what we could check. It is not medical advice and not a recommendation to use it.
Every telehealth brand we rank gets the same five checks, read from its public pages on September 24, 2026. "Not met" means we did not find it, or the terms say otherwise, on the pages we could read. Price and commission play no part.
No price is shown on the homepage.
Names Dr. Aaron Carter, MD as chief medical officer and Sarah Jenkins as a prescriber.
Names no pharmacy on the pages we read.
The homepage promises your money back if you do not lose 10% of body weight within six months. We did not read the full terms.
No warning letter under this name in FDA's public database on September 24, 2026.
Graded by whether we could confirm it ourselves or are only repeating what the vendor states. A vendor's honesty about its own testing is a different question from what a published trial shows, so this is a separate scale from the evidence grades on our guides.
The page bases this on an internal analysis of 6,846 members at 10 months. That is higher than the 72-week averages in the published tirzepatide trial (15.0% to 20.9%), and we cannot tell whether the analysis includes people who stopped earlier.
Where the vendor states thisBoth are superlatives on the brand's own page. We found no source for the ranking or the review count.
Where the vendor states thisStated on the homepage. We confirmed this ourselves.
Where the vendor states thisFDA does not review compounded drugs for safety, effectiveness or quality before they are sold. In 2026 FDA warned 30 telehealth companies over claims implying sameness with approved drugs, and proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, so the legal footing of this category can change.
The 21.5% average and 'No. 1' claim come from the brand's own analysis and wording.
You have to start the assessment to see what the protocol costs.
No. HumeCare+ is a GLP-1 weight-loss program and Hume Health sells body-composition hardware. They are separate brands, and we review Hume Health's scale and band on its own page.
Every fact above traces to one of these pages, published by the vendor itself and checked on September 21, 2026. Vendor policy pages change without notice, so if something here looks out of date, it probably is.
Compare against
Open pricing, public COAs, strict research-only gate
